stoxline Quote Chart Rank Option Currency Glossary
Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
33.69  0.7 (2.12%)    06-18 10:48
Open: 33.22
High: 34.24
Volume: 195,690
Pre. Close: 32.99
Low: 33.01
Market Cap: 2,975(M)
Technical analysis
2024-06-18 10:17:46 AM
Short term     
Mid term     
Targets 6-month :  41.45 1-year :  47.72
Resists First :  35.48 Second :  40.86
Pivot price 34.02
Supports First :  26.79 Second :  22.29
MAs MA(5) :  33.52 MA(20) :  34.91
MA(100) :  45.09 MA(250) :  34.81
MACD MACD :  -1.7 Signal :  -1.9
%K %D K(14,3) :  55.8 D(3) :  53
RSI RSI(14): 41.6
52-week High :  62.2 Low :  16.45
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ BHVN ] has closed above bottom band by 37.0%. Bollinger Bands are 70.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 33.95 - 34.13 34.13 - 34.29
Low: 32.35 - 32.62 32.62 - 32.84
Close: 32.6 - 32.99 32.99 - 33.31
Company Description

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.

Headline News

Fri, 14 Jun 2024

Wed, 12 Jun 2024
Biohaven's (BHVN) Zavegepant NDA for Migraine Accepted by FDA - Yahoo Singapore News

Thu, 09 May 2024
Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments - PR Newswire

Thu, 29 Feb 2024
Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments - PR Newswire

Wed, 04 Oct 2023
Biohaven (BHVN) prices its $225m public offering of common shares - Leaprate Forex Trading News

Mon, 03 Oct 2022
Pfizer Completes Acquisition of Biohaven Pharmaceuticals - Business Wire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 88 (M)
Shares Float 77 (M)
Held by Insiders 12.8 (%)
Held by Institutions 85.8 (%)
Shares Short 9,240 (K)
Shares Short P.Month 8,910 (K)
Stock Financials
EPS -6.91
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.68
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -65.3 %
Return on Equity (ttm) -133.7 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -6.06
Qtrly Earnings Growth 0 %
Operating Cash Flow -357 (M)
Levered Free Cash Flow -214 (M)
Stock Valuations
PE Ratio -4.88
PEG Ratio 0
Price to Book value 9.14
Price to Sales 0
Price to Cash Flow -8.33
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android